Osteopontin and osteocalcin in lung cancer


  • O.Yu. Stoliarova National Cancer Institute, Kyiv, Ukraine




cancer, lungs, osteopontin, osteocalcin


Background. Lung cancer (LC) occupies a leading position in the structure of cancer morbidity and is one of the leading causes of death. Search for effective approaches to assess the course of LC using informative criteria is a topical task of modern oncology. LC usually develops with increased level of osteopontin (OP) and osteocalcin (OC) in the blood, which has prognostic significance in the framework of survival of patients. The serum content of these osteooncomarkers is directly associated with presence of metastases in patients and rapid
progression of the disease, but these data need further clarifi­cation. Purpose of the study was to evaluate clinical-pathogenetic and prognostic significance of OP and OC in patients with different variants of LC course. Materials and methods. 115 patients with LC aged from 24 to 80 (average age 58 years old) were examined, among which there were 78 % of men and 22 % of women. None of the patients were operated for LC previously and before the examination receive radiochemotherapy. Small-cell histological variant of the disease was found in 17 % of cases and non-small-cell — in 83 %. Immunoassay analysis was used to study the levels of OP and OC in the blood serum and vascular endothelial growth factor (VEGF). Results. In patients with LC, the values of oncoosteoassociated markers OP and OC in the serum increased, which were observed in 99 and 98 % of cases, respectively. Changes in OP and OC were associated with the form of the disease, its histological variant, degree of differentiation, integrated severity of LC course, nature of primary tumor complications and peculiarities of metastasis. A high level of markers in the blood had little effect on three-year survival of patients, and OP parameters are prognostic criteria for LC course. OP and OC values in the blood directly correlated with each other, and OP content, in addition, had posi­tive relationships with such tumor marker as VEGF, which refers to the stimulants of neoangiogenesis. Metastatic lesion of skeleton and development of cerebral circulation disorders as a result of subsequent radiochemotherapy was directly related to high concentration of OP in the blood, which is a risk factor for other treatment complications. Conclusion. High levels of OP and OC in the blood have important clinical and pathogene­tic significance in LC. Study of these osteooncomarkers indices will contribute to early diagnosis of specific signs of the disease progression, improvement of quality of timely diagnosis of metastasis in the musculoskeletal system and prediction of possible radiochemotherapy complications.


Download data is not yet available.


Ayan AK, Erdemci B, Orsal E, et al. Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis? Rev Esp Med Nucl Imagen Mol. 2015;27(10):182-8. doi: 10.1016/j.remn.2015.09.002.

Bauer NB, Khassawna TE, Goldmann F, et al. Characterization of bone turnover and energy metabolism in a rat model of primary and secondary osteoporosis. Exp Toxicol Pathol. 2015;67(4):287-96. doi: 10.1016/j.etp.2015.01.004.

Ceniceros L, Aristu J, Castanon E, et al. Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients. Clin Transl Oncol. 2015;55(8):213-9. doi: 10.1186/s13014-015-0417-5.

Domigan CK, Warren CM, Antanesian V, et al. Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy. J Cell Sci. 2015:128(12):2236-48. doi: 10.1242/jcs.163774.

Fan X, Jia C, Yang J, et al. A microfluidic chip integrated with a high-density PDMS-based microfiltration membrane for rapid isolation and detection of circulating tumor cells. Biosens Bioelectron. 2015;71(15):380-6. doi: 10.1016/j.bios.2015.04.080.

Grаdalska-Lampart M, Karczmarek-Borowska B, Radziszewska AU. Lung cancer in Podkarpackie region in the years 2002-2011. Pneumonol Alergol Pol. 2015;83(2):109-19. doi: 10.5603/PiAP.2015.0018.

Kang CG, Han HJ, Lee HJ, Kim SH, Lee EO. Rho-associated kinase signaling is required for osteopontin-induced cell invasion through inactivating cofilin in human non-small cell lung cancer cell lines. Bioorg Med Chem Lett. 2015;25(9):1956-60. doi: 10.1016/j.bmcl.2015.03.024.

Klahan S, Kuo CN, Chien SC, et al. Osteoporosis increases subsequent risk of gallstone: a nationwide population-based cohort study in Taiwan. BMC Gastroenterol. 2014;18(14):192-9. doi: 10.1186/s12876-014-0192-z.

Li Y, Sun BS, Pei B, Li CG, Zhang ZF, Yin YS. Osteopontin-expressing macrophages in non-small cell lung cancer predict survival. Ann Thorac Surg. 2015;99(4):1140-8. doi: 10.1016/j.athoracsur.2014.11.054.

Lin Q, Xue L, Tian T, et al. Prognostic value of serum IL-17 and VEGF levels in small cell lung cancer. Int J Biol Markers. 2015;30(7):165-75. doi: 10.5301/jbm.5000148.

Neal JW, Gainor JF, Shaw AT. Developing biomarker-specific аnd points in lung cancer clinical trials. Nat Rev Clin Oncol. 2015;12(3):135-46. doi: 10.1038/nrclinonc.2014.222.

Ostheimer C, Bache M, Güttler A, Reese T, Vordermark D. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 2014;14:858. doi: 10.1186/1471-2407-14-858.

Peng B, Wang YH, Huang Z, Feng SJ, Wang YS. Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis. Int J Clin Exp Med 2014;7(12):4616-26. PMID: 25663958.

Rizzoli R, Body JJ, Brandi ML, et al. Cancer-associated bone disease. Osteoporos Int. 2013;24(12):2929-53. doi: 10.1007/s00198-013-2530-3.

Shen W, Yin R, Wang C, et al. Polymorphisms in alternative splicing associated genes are associated with lung cancer risk in a Chinese population. Lung Cancer. 2015;89(3):238-42. doi: 10.1016/j.lungcan.2015.06.010.

Su Y, Zhang H, Xu F, Kong J, Yu H, Qian B. DNA repair gene polymorphisms in relation to non-small cell lung cancer survival. Cell Physiol Biochem. 2015;36(4):1419-29. doi: 10.1007/s12094-014-1183-9.

Sun B, Zhang Z. Advances in research of osteopontion and its receptor CD44v in tumor invasion and metastasis. Zhongguo Fei Ai Za Zhi. 2015;18(11):714-7. doi: 10.3779/j.issn.1009-3419.2015.11.11.

Ulas A, Turkoz FP, Silay K, et al. A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One. 2014;9(12):114471. doi: 10.1371/journal.pone.0114471.

Xie D, Marks R, Zhang M, et al. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol. 2015;10(8):1213-20. doi: 10.1097/JTO.0000000000000585.

Zhang B, Dai J, Wang H, Wei H, Zhao J, Guo Y. Anti-osteopontin monoclonal antibody prevents ovariectomy-induced osteoporosis in mice by promotion of osteoclast apoptosis. Biochem Biophys Res Commun. 2014;452(3):795-800. doi: 10.1016/j.bbrc.2014.08.149.



How to Cite

Stoliarova, O. (2021). Osteopontin and osteocalcin in lung cancer. PAIN, JOINTS, SPINE, 7(4), 167–171. https://doi.org/10.22141/2224-1507.7.4.2017.121228



Original Researches

Most read articles by the same author(s)